{"id":763432,"title":"Archived 33: Summary of NACI statement of February 17, 2022: Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-03-02","captureTimestamp":"2026-03-02T23:07:15.097000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-novavax-nuvaxovid-covid-19-vaccine/summary-february-17-2022.html","snippet":"Archived 33: Summary of NACI statement of February 17, 2022: Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine Notice to reader This is an archived version. Please refer to current COVID-19 vaccine pages: NACI statements and publications COVID-19 vaccine: Canadian…","rawSnapshotUrl":"/api/snapshots/raw/763432","browseUrl":"https://replay.healtharchive.ca/job-7/20260302230715/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-novavax-nuvaxovid-covid-19-vaccine/summary-february-17-2022.html#ha_snapshot=763432","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}